Deniz Demircioglu

Title: Deniz Demircioglu: Innovator in Cancer Therapy

Introduction

Deniz Demircioglu is a notable inventor based in Singapore, recognized for his contributions to cancer therapy. He has developed a significant patent that aims to improve patient outcomes in immune checkpoint inhibition therapy. His work reflects a commitment to advancing medical science and enhancing treatment efficacy for cancer patients.

Latest Patents

Deniz holds a patent titled "Method of predicting for benefit from immune checkpoint inhibition therapy." This invention relates to a method of identifying whether a cancer patient will benefit from immune checkpoint inhibition therapy. The process involves measuring the expression level of specific markers in a cancerous biological sample, identifying a differentially expressed alternative promoter, calculating an alternative promoter usage score, and determining the patient's benefit from the therapy based on this score. Additionally, the invention includes a biomarker for excluding patients from this therapy when it is deemed unsuitable.

Career Highlights

Throughout his career, Deniz has worked with esteemed organizations such as the Agency for Science, Technology and Research and the National University Hospital (Singapore) Pte. Ltd. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Deniz has collaborated with notable colleagues, including Patrick Tan and Raghav Sundar. These partnerships have fostered an environment of innovation and have been instrumental in the development of his patent.

Conclusion

Deniz Demircioglu's work in cancer therapy exemplifies the impact of innovative thinking in medicine. His patent not only advances the understanding of patient responses to treatment but also highlights the importance of research in improving healthcare outcomes.